SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros is trending as the community celebrates the FDA approval of YARTEMLEA, the first and only therapy for transplant-associated thrombotic microangiopathy in adults and children, sparking immense optimism among long-term investors. Many are eagerly discussing the potential for a significant re-rating of the company's valuation and a substantial short squeeze. This milestone, coupled with a multi-billion dollar partnership, has led to widespread belief that the company is now de-risked and poised for considerable growth.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

KTA CRYPTO is drawing significant attention as a Layer 1 network building high-speed, compliance-first financial infrastructure, with a recent integration of a fiat anchor from a Stripe company enabling seamless transfers. The community is actively discussing its potential as an undervalued "asymmetric bet" set to become a foundational layer for global financial plumbing. This positioning, coupled with its proven throughput and regulatory readiness, makes it a compelling opportunity amidst the evolving crypto landscape.

Citigroup, Inc. is a holding company, which engages in the provision of financial products and services. It operates through the following segments: Services, Markets, Banking, Wealth, U.S. Personal Banking (USPB), and All Other. The Services segment includes Treasury and Trade Solutions (TTS) which provides an integrated suite of tailored cash management, trade, and working capital solutions to multinational corporations, financial institutions and public sector organizations, and Securities Services, which offers cross-border support for clients, providing on-the-ground local market expertise, post-trade technologies, customized data solutions, and a wide range of securities services solutions that can be tailored to meet client needs. The Markets segment provides corporate, institutional, and public sector clients around the world with a full range of sales and trading services across equities, foreign exchange, rates, spread products, and commodities. The Banking segment offers Investment Banking and Corporate Lending services. The Wealth segment includes Private Bank, Wealth at Work, and Citigold and provides financial services to a range of client segments through banking, lending, mortgages, investment, custody, and trust product offerings. The USPB segment includes Branded Cards and Retail Services, which have proprietary card portfolios and co-branded card portfolios within Branded Cards, and co-brand and private label relationships within Retail Services. The All Other segment consists of activities not assigned to the reportable operating segments, including certain unallocated costs of global functions, other corporate expenses, and net treasury results. The company was founded in 1812 and is headquartered in New York, NY.

Citigroup Inc

Citigroup is experiencing significant upward momentum, driven by recent regulatory relief, its ongoing strategic transformation, and strong Q3 earnings reported across the financial sector. This rally has propelled the stock to multi-year highs, sparking community debate about its sustainability amidst indicators of overbought conditions and discussions around notable corporate buybacks.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending following the successful orbital launch of its BlueBird 6 satellite, a major milestone for direct-to-device 4G/5G connectivity from low Earth orbit. Despite the positive news, the stock experienced a "sell the news" dip, leading to community debate between short-term profit-takers and long-term investors who highlight future launches and the de-risking of ASTS's technology.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax Technologies is trending following a definitive agreement for acquisition by Sanofi for a notable cash value, which sent the stock surging. The community is actively discussing the offer, with many long-term shareholders expressing mixed sentiments: celebrating significant gains while a vocal segment believes the valuation is too low given the company's Hepatitis B vaccine, Heplisav-B, and promising shingles vaccine candidate.

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Aquestive Therapeutics Inc

Aquestive Therapeutics is a hot topic as its Anaphylm approval decision for anaphylaxis looms, with the PDUFA date nearing. Community sentiment is sharply divided between high confidence in a breakthrough needle-free oral film and concerns over previous regulatory setbacks and substantial short interest, as debate continues with competitor SPRY's nasal spray. Many are actively discussing Anaphylm's potential to redefine epinephrine delivery and its significant long-term value.

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Biohaven Ltd

Biohaven Pharmaceutical Holding Company Ltd

Biohaven is trending as substantial insider buying, coupled with a public offering, conveys management's confidence despite a regulatory complete response letter for one of its lead programs. Community discussion is further energized by encouraging early clinical data for its experimental cancer treatment, BHV-1510, which demonstrated notable response rates and a favorable safety profile. Investors are now closely watching for upcoming readouts from its major depressive disorder and epilepsy programs for additional catalysts.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Agios Pharmaceuticals Inc

Agios Pharmaceuticals is trending following its recent FDA approval of Aqvesme, establishing it as the sole approved treatment for anemia in alpha- and beta-thalassemia. While the community is excited about this significant milestone, discussion is also focusing on the immediate stock dip, attributed to the mandated Risk Evaluation and Mitigation Strategy (REMS) program and a delayed commercial availability into early 2026.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences (GLSI) is trending after promising preliminary Phase 3 data for its breast cancer immunotherapy showed an estimated 80% reduction in recurrence rates, driving intense bullish sentiment. The community is actively discussing perceived undervaluation, continued insider buying by the CEO, and the escalating potential for a significant short squeeze, fueled by exceptionally high borrow rates and a tightly held float.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending after Apple CEO Tim Cook's significant stock purchase, which many in the community interpret as a strong insider vote of confidence and a potential signal for a turnaround. While some view this as marking a significant bottom and anticipate a rally, others remain skeptical, pointing to persistent concerns over China sales, tariffs, and the company's valuation, sparking a polarized discussion on its near-term prospects.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Travelers (TRV) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

MCY Stock Near 52-Week High: Time to Add it for Better Returns?

Mercury General gains from rising premiums, strong P&C performance, and solid investment income, which highlight sustained financial strength.

Voya Investment Management LLC Has $10.76 Million Position in The Travelers Companies, Inc. $TRV

Voya Investment Management LLC lessened its stake in shares of The Travelers Companies, Inc. (NYSE:TRV - Free Report) by 19.1% in the third quarter, according to the company in its most recent filing...

Zacks Research Downgrades Travelers Companies (NYSE:TRV) to Hold

Zacks Research downgraded Travelers Companies from a "strong-buy" rating to a "hold" rating in a research note on Monday...

Patton Fund Management Inc. Trims Position in The Travelers Companies, Inc. $TRV

Patton Fund Management Inc. decreased its position in shares of The Travelers Companies, Inc. (NYSE:TRV - Free Report) by 90.1% during the third quarter, according to the company in its most recent...

Are Investors Undervaluing The Travelers Companies (TRV) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Abner Herrman & Brock LLC Makes New $1.17 Million Investment in The Travelers Companies, Inc. $TRV

Abner Herrman & Brock LLC bought a new stake in The Travelers Companies, Inc. (NYSE:TRV - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange...

The Travelers Companies, Inc. (NYSE:TRV) Given Average Recommendation of "Hold" by Analysts

The Travelers Companies, Inc. (NYSE:TRV - Get Free Report) has received a consensus recommendation of "Hold" from the twenty research firms that are currently covering the firm, MarketBeat Ratings...

Corsicana & Co. Invests $1.59 Million in The Travelers Companies, Inc. $TRV

Corsicana & Co. bought a new stake in The Travelers Companies, Inc. (NYSE:TRV - Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The...

Osaic Holdings Inc. Has $13.27 Million Stock Holdings in The Travelers Companies, Inc. $TRV

Osaic Holdings Inc. reduced its position in shares of The Travelers Companies, Inc. (NYSE:TRV - Free Report) by 14.4% during the 2nd quarter, according to the company in its most recent Form 13F...

The Travelers Cos., Inc. is a holding company, which engages in the provision of commercial and personal property and casualty insurance products and services. It operates through the following business segments: Business Insurance, Bond and Specialty Insurance, and Personal Insurance. The Business Insurance segment offers an array of property and casualty insurance, and insurance related services to its customers primarily in the U.S., as well as in Canada, the United Kingdom, the Republic of Ireland and throughout other parts of the world as a corporate member of Lloyd's. The Bond and Specialty Insurance segment includes surety, fidelity, management liability, professional liability, and other property and casualty coverage and related risk management services. The Personal Insurance segment is involved in a range of property and casualty insurance products and services covering individuals' personal risks, primarily in the U.S. and Canada. The company was founded in 1853 and is headquartered in New York, NY.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	$8.48	--	--	N/A
Q3 '25	$6.39	$8.14	27.40%	BEAT
Q2 '25	$3.65	$6.51	78.29%	BEAT
Q1 '25	$0.79	$1.91	143.26%	BEAT
Q4 '24	$6.63	$9.15	38.04%	BEAT

TRV
Travelers Companies Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest TRV News

TRVTravelers Companies Inc.